BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29273958)

  • 1. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
    Colomer R; Aranda-López I; Albanell J; García-Caballero T; Ciruelos E; López-García MÁ; Cortés J; Rojo F; Martín M; Palacios-Calvo J
    Clin Transl Oncol; 2018 Jul; 20(7):815-826. PubMed ID: 29273958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
    Palacios Calvo J; Albanell J; Rojo F; Ciruelos E; Aranda-López I; Cortés J; García-Caballero T; Martín M; López-García MÁ; Colomer R
    Rev Esp Patol; 2018; 51(2):97-109. PubMed ID: 29602380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
    Colomer R; González-Farré B; Ballesteros AI; Peg V; Bermejo B; Pérez-Mies B; de la Cruz S; Rojo F; Pernas S; Palacios J
    Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38869741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive biomarkers in breast cancer: Past, present and future.
    Nicolini A; Ferrari P; Duffy MJ
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):56-73. PubMed ID: 28882552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
    Duffy MJ; Harbeck N; Nap M; Molina R; Nicolini A; Senkus E; Cardoso F
    Eur J Cancer; 2017 Apr; 75():284-298. PubMed ID: 28259011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).
    García-Alfonso P; Salazar R; García-Foncillas J; Musulén E; García-Carbonero R; Payá A; Pérez-Segura P; Ramón y Cajal S; Navarro S; ;
    Clin Transl Oncol; 2012 Oct; 14(10):726-39. PubMed ID: 22855150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multigene prognostic tests in breast cancer: past, present, future.
    Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
    Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gene signatures for breast cancer, clinical utility and therapeutic applications].
    Vargas-Aguilar VM; Arroyo-Alvarez K
    Rev Med Inst Mex Seguro Soc; 2018; 56(2):180-185. PubMed ID: 29906029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
    Krop I; Ismaila N; Andre F; Bast RC; Barlow W; Collyar DE; Hammond ME; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Wolff AC; Stearns V
    J Clin Oncol; 2017 Aug; 35(24):2838-2847. PubMed ID: 28692382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    García-Alfonso P; García-Foncillas J; Salazar R; Pérez-Segura P; García-Carbonero R; Musulén-Palet E; Cuatrecasas M; Landolfi S; Ramón Y Cajal S; Navarro S; ;
    Clin Transl Oncol; 2015 Apr; 17(4):264-73. PubMed ID: 25373533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
    García-Alfonso P; García-Carbonero R; García-Foncillas J; Pérez-Segura P; Salazar R; Vera R; Ramón Y Cajal S; Hernández-Losa J; Landolfi S; Musulén E; Cuatrecasas M; Navarro S
    Clin Transl Oncol; 2020 Nov; 22(11):1976-1991. PubMed ID: 32418154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    Remon J; García-Campelo R; de Álava E; Vera R; Rodríguez-Peralto JL; Rodríguez-Lescure Á; Bellosillo B; Garrido P; Rojo F; Álvarez-Alegret R
    Clin Transl Oncol; 2020 Jun; 22(6):823-834. PubMed ID: 31559582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany.
    Lux MP; Minartz C; Müller-Huesmann H; Sandor MF; Herrmann KH; Radeck-Knorre S; Neubauer AS
    Cancer Treat Res Commun; 2022; 31():100519. PubMed ID: 35093682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Testing in Breast Cancer: A Guide to Current Practices.
    Hagemann IS
    Arch Pathol Lab Med; 2016 Aug; 140(8):815-24. PubMed ID: 27472240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC).
    Barnadas A; Algara M; Cordoba O; Casas A; Gonzalez M; Marzo M; Montero A; Muñoz M; Ruiz A; Santolaya F; Fernandez T
    Clin Transl Oncol; 2018 Jun; 20(6):687-694. PubMed ID: 29139040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
    Vera-Badillo FE; Chang MC; Kuruzar G; Ocana A; Templeton AJ; Seruga B; Goldstein R; Bedard PL; Tannock IF; Amir E
    J Clin Pathol; 2015 Oct; 68(10):839-43. PubMed ID: 26076967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.